LAKE ZURICH, Ill.--(BUSINESS WIRE)-- Fresenius Kabi announced today the immediate availability of Temsirolimus Injection in the United States. Fresenius Kabi’s Temsirolimus Injection is supplied as a kit including one vial of 25 mg/mL Temsirolimus solution and one vial of diluent.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210521005009/en/

Temsirolimus, for the treatment of renal cancer, is now available in the U.S. from Fresenius Kabi. It is the latest addition to the company's large U.S. portfolio of generic injectable oncology products. (Photo: Business Wire)

Temsirolimus, for the treatment of renal cancer, is now available in the U.S. from Fresenius Kabi. It is the latest addition to the company's large U.S. portfolio of generic injectable oncology products. (Photo: Business Wire)

Temsirolimus Injection, a generic version of the brand Torisel®, is used to treat advanced renal cell carcinoma. It is the newest addition to the most comprehensive injectable oncology portfolio in America.

“Fresenius Kabi is committed to expanding affordable treatment options for patients,” said John Ducker, president and CEO of Fresenius Kabi USA. “The addition of Temsirolimus is the most recent example of our development program and deep expertise in oncology medicines. Fresenius Kabi is pleased to continue to develop high-quality therapies that clinicians can deliver knowing they are safe, efficacious and accessible for their patients.”

Fresenius Kabi is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. The company offers a broad portfolio of generic injectable oncology medicines and has a pipeline that includes biosimilars and complex generics for oncology patients.

References:

https://www.biospace.com/article/releases/temsirolimus-injection-now-available-from-fresenius-kabi/